但国资入主并未带来稳定，胜帮英豪在入主派林生物后着手对董事会"换血"，再次引发与付绍兰等原董 事会成员的争端。详见《董事长和控股股东"各执一词" 派林生物内部纷争将走向何方？》。 后经多方协调，派林生物在2023年12月发布公告称，前董事长付绍兰以联席董事长身份再次回到了董事 会，这场历时近一年的股东纷争才得以平息。 据派林生物今晚公告，公司近日收到控股股东共青城胜帮英豪投资合伙企业（有限合伙）（简称"胜帮 英豪"）的通知，其正在筹划涉及公司控制权变更的事项。由于上述事项尚在筹划中，尚未签署协议， 具有较大不确定性，公司股票自6月6日（星期五）开市起停牌，预计停牌时间不超过2个交易日。 智通财经记者了解到，这是派林生物七年内第三次面临控制权变更。 据公司2024年年度报告，公司控股股东1998年变更为三九企业集团；2002年变更为三九医药股份有限公 司；2007年变更为振兴集团有限公司；2018年变更为杭州浙民投天弘投资合伙企业（有限合伙）；2023 年变更为目前的共青城胜帮英豪投资合伙企业（有限合伙）。 具体而言，派林生物的股权动荡始于2018年。彼时浙民投通过资产重组入主，推动收购东北血制品企业 派斯菲科 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-028 派斯双林生物制药股份有限公司 关于筹划控制权变更事项的停牌公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 特别提示： 特此公告。 派斯双林生物制药股份有限公司 董 事 会 二〇二五年六月六日 1 1、公司股票自2025年6月6日开市起停牌，预计停牌时间不超过2个交易日。 2、公司控制权变更事项目前处于筹划阶段，尚存在较大不确定性，敬请广大投资 者注意投资风险。 公司近日收到控股股东共青城胜帮英豪投资合伙企业（有限合伙）的通知，其正在 筹划涉及公司控制权变更的事项。 上述事项尚在筹划中，尚未签署协议，具有较大不确定性。为保证公平信息披露， 维护投资者利益，避免公司股价异常波动，根据《深圳证券交易所股票上市规则》及《深 圳证券交易所上市公司自律监管指引第6号——停复牌》的相关规定，经公司向深圳证 券交易所申请，公司股票（股票简称：派林生物，股票代码：000403）自2025年6月6日 （星期五）开市起停牌，预计停牌时间不超过2个交易日。 停牌期间，公司将根据相关事项进展情况，严格按照法 ...

Core Viewpoint - The company is planning a change in control, leading to a temporary suspension of its stock trading starting June 6, 2025, to ensure fair information disclosure and protect investor interests [1]. Group 1 - The company received a notification from its controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership (Limited Partnership), regarding the planning of a change in control [1]. - The stock will be suspended for trading for a period not exceeding two trading days starting from June 6, 2025 [1]. - The change in control is currently in the planning stage and carries significant uncertainty [1].

Core Viewpoint - The company, Pailin Bio (000403), has announced that its controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, is planning a change in the company's control, which is still in the planning stage and has not yet signed any agreements, indicating significant uncertainty [1] Group 1 - The company has received a notification from its controlling shareholder regarding the potential change in control [1] - The matter is still under planning and has not reached the agreement stage, highlighting the uncertainty involved [1] - To ensure fair information disclosure and protect investor interests, the company's stock will be suspended from trading starting June 6, 2025, for a period not exceeding 2 trading days [1] Group 2 - During the suspension period, the company will fulfill its information disclosure obligations and will release relevant announcements once the matter is confirmed [1] - The company will apply for resumption of trading after the relevant matters are determined [1]

Group 1 - The company held its 15th meeting of the 10th Board of Directors on May 30, 2025, via communication method, with all 13 directors present [1] - The Board discussed and approved a report regarding the rectification of issues pointed out in the administrative regulatory measures decision by the Shanxi Securities Regulatory Bureau, emphasizing compliance and internal control improvements [1][2] - The company aims to strictly adhere to relevant regulations, enhance operational awareness, and strengthen management of subsidiaries to protect the interests of the company and its shareholders [1]

证券代码：000403 证券简称：派林生物 公告编号：2025-027 派斯双林生物制药股份有限公司 关于对山西证监局行政监管措施决定书的整改报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）于近日收到中国证券监督管 理委员会山西监管局（以下简称"山西证监局"）出具的《关于对派斯双林生物制药 股份有限公司采取责令改正措施的决定》（[2025]18 号）（以下简称"《行政监管措 施决定书》"），具体内容详见公司于 2025 年 5 月 12 日发布的《关于收到山西证监 局行政监管措施决定书的公告》（公告编号：2025-022）。 公司对此高度重视，及时向公司董事、监事、高级管理人员和涉及人员进行了通 报，并针对行政监管措施决定书中涉及问题进行了全面梳理和整改，公司于 2025 年 5 月 30 日召开第十届董事会第十五次会议审议通过了《关于审议<中国证券监督管理委 员会山西监管局行政监管措施决定书的整改报告>的议案》，现将整改报告情况报告 如下： 一、 问题及整改情况 （一）是公司子公司与个别客户及推广商针对 ...

一、董事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届董事会第十五次会议 于 2025 年 5 月 30 日以通讯方式召开，会议由公司董事长李昊先生召集并主持。会议 应出席董事 13 人，实际出席董事 13 人，会议程序符合《公司法》和《公司章程》的 有关规定。 二、董事会会议审议情况 证券代码：000403 证券简称：派林生物 公告编号：2025-026 派斯双林生物制药股份有限公司 第十届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 三、备查文件 第十届董事会第十五次会议决议。 特此公告。 1 与会董事经过认真讨论，审议了以下议案： 1、《关于审议<中国证券监督管理委员会山西监管局行政监管措施决定书的整改 报告>的议案》 公司高度重视行政监管措施决定书中所指出的违规问题，已积极进行整改并明确 管理要求，董事会同意关于《中国证券监督管理委员会山西监管局行政监管措施决定 书的整改报告》。未来将严格遵守相关规定，提高规范运作意识，加强内控合规管理， 强化子公司规范管理，严格履行信息披露义务，切实维护公司及全 ...

关于2024年度利润分配实施的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股东大会审议通过利润分配方案的相关情况 1、派斯双林生物制药股份有限公司（以下简称"公司"或"本公司"）2024年度 利润分配方案已获2025年5月21日召开的2024年度股东大会审议通过，具体内容为： 以2025年4月20日公司的总股本731,074,913股为基数，按每10股派发现金红利3.5元（含 税）向全体股东分配，共派发现金255,876,219.55元，现金分红金额占2024年度归属于 上市公司股东的净利润的比率为34.33%，剩余未分配利润结转以后年度。2024年度每 10股以资本公积金转增3股，不送红股，本次转增后公司总股本为950,397,387股，转增 金额未超过2024年末资本公积—股本溢价的余额。根据《深圳证券交易所上市公司自 律监管指引第1号——主板上市公司规范运作》的规定，在利润分配方案公布后至实 施前，出现股权激励行权、可转债转股、股份回购等情形时，公司将按照"现金分红 金额、送红股金额、资本公积金转增股本金额固定不变"的原则进行方案调整。 ...

Core Viewpoint - Taiyuan City is focusing on industrial transformation and the cultivation of strategic emerging industries, enhancing innovation and establishing a green manufacturing system to drive high-quality economic development [1][31]. Group 1: Macroeconomic Analysis - Taiyuan's GDP for 2024 is projected to be CNY 541.887 billion, with a growth rate of 1.2%. The primary, secondary, and tertiary industries contribute CNY 4.785 billion, CNY 166.671 billion, and CNY 370.431 billion respectively, with the tertiary sector growing by 1.6% [2][4]. - The proportion of strategic emerging industries in Taiyuan's industrial output is increasing, with a 2024 forecast showing a 37.3% contribution to the total industrial output, up 1.4 percentage points from the previous year [4]. Group 2: Investment Trends - Fixed asset investment in Taiyuan is expected to grow by 0.5% in 2024, with 136 ongoing projects valued over CNY 1 billion, representing 35.9% of total investment [6]. - Industrial investment is projected to account for 27.7% of total investment, with a significant increase of 24.7% year-on-year [6]. Group 3: Industrial Structure - Taiyuan is constructing a modern industrial system centered around the "1233" key industrial chain system, which includes nine major industrial chains contributing approximately 70% of the city's industrial output [10][31]. - The "1233" system focuses on high-end metal materials, advanced carbon-based materials, and advanced biological materials, among others, with 118 key enterprises involved [10][31]. Group 4: Innovation and R&D - In 2023, Taiyuan's R&D expenditure reached CNY 12.79 billion, ranking first in Shanxi Province, indicating a strong focus on innovation [8]. - The city is implementing four major projects to enhance innovation capabilities, including optimizing the innovation ecosystem and promoting the transformation of innovative results [8]. Group 5: Key Industries - The high-end metal materials industry is a pillar of Taiyuan's economy, with significant products including special steel and new magnesium alloys, generating CNY 118.3 billion in revenue in 2023 [19][20]. - The carbon-based materials industry is leveraging local coal resources and advanced research capabilities, with a focus on both traditional and cutting-edge carbon materials [25][27]. - The advanced biological materials and biopharmaceutical industry is developing rapidly, focusing on bio-based new materials and recombinant human collagen protein [29]. Group 6: Policy Framework - Taiyuan has introduced several policies to support high-quality development, including plans for digital transformation and the establishment of advanced manufacturing bases [16][18]. - The city aims to achieve significant results in industrial high-quality development by 2025, enhancing its competitive advantages [16].

Core Viewpoint - The blood products market is experiencing intense competition due to its vast potential, leading to both external corporate rivalries and internal conflicts within companies like Pailin Biological [2][3]. Company Overview - Pailin Biological, a leading player in the blood products sector, has faced regulatory penalties due to internal control deficiencies, with key executives held accountable [2][6]. - The company reported a revenue decline of 14.00% and a net profit drop of 26.95% in Q1 2025, ending a six-year streak of positive net profit growth since 2018 [2][14]. Financial Performance - Pailin Biological's revenue and net profit figures from 2020 to 2024 show fluctuations, with a notable revenue of 26.55 billion yuan in 2024, marking a 14.00% increase year-on-year, and a net profit of 7.45 billion yuan, up 21.76% [7][8]. - The company’s revenue in 2023 was 23.29 billion yuan, a slight decrease of 3.18%, while net profit grew by 4.25% to 6.12 billion yuan [8]. Market Dynamics - The blood products market is projected to exceed 60 billion yuan in 2024, with an expected annual compound growth rate of 9.89% from 2024 to 2031, driven by increasing demand due to aging populations and rising incidences of diseases [10][11]. - The industry faces challenges in plasma supply, with the number of operational single plasma collection stations increasing from approximately 220 in 2016 to 320 in 2024, yet still insufficient to meet market demand [11]. Strategic Developments - Pailin Biological is expanding its production capacity, with plans for 3,100 tons of new capacity to be gradually put into operation by mid-2025, which is expected to alleviate supply pressures and support future growth [12][14]. - The company is also focusing on high-value products, such as recombinant coagulation factor VIII, to enhance profit margins, despite the competitive and technologically demanding nature of the blood products industry [14].